tiprankstipranks
Advertisement
Advertisement

RZLT Stock Latest News

Midday Fly By: Merck to acquire Terns, Arm CPU launch applauded
The FlyMidday Fly By: Merck to acquire Terns, Arm CPU launch applauded
20d ago
GM
AMD
Wedbush upgrades Rezolute as worst case scenario seems unlikely for cHI
PremiumThe Fly
Wedbush upgrades Rezolute as worst case scenario seems unlikely for cHI
20d ago
RZLT
Rezolute upgraded to Outperform from Neutral at Wedbush
PremiumThe Fly
Rezolute upgraded to Outperform from Neutral at Wedbush
20d ago
RZLT
Rezolute Prepares FDA Submission After sunRIZE Trial Review
PremiumCompany Announcements
Rezolute Prepares FDA Submission After sunRIZE Trial Review
21d ago
8K
RZLT
Rezolute provides update on sunRIZE study following Type B meeting with FDA
PremiumThe Fly
Rezolute provides update on sunRIZE study following Type B meeting with FDA
21d ago
RZLT
Rezolute management to meet with Maxim
PremiumThe FlyRezolute management to meet with Maxim
1M ago
RZLT
Rezolute: Positive Risk‑Reward Outlook Despite sunRIZE Miss, Backed by Encouraging Hyperinsulinism Data and Solid Cash Position
Premium
Ratings
Rezolute: Positive Risk‑Reward Outlook Despite sunRIZE Miss, Backed by Encouraging Hyperinsulinism Data and Solid Cash Position
2M ago
RZLT
Rezolute reports Q2 EPS (22c), consensus (18c)
Premium
The Fly
Rezolute reports Q2 EPS (22c), consensus (18c)
2M ago
RZLT
RZLT Earnings this Week: How Will it Perform?
PremiumPre-Earnings
RZLT Earnings this Week: How Will it Perform?
2M ago
RZLT
Rezolute price target raised to $2 from $1 at Wedbush
PremiumThe Fly
Rezolute price target raised to $2 from $1 at Wedbush
3M ago
RZLT
Maintaining a Buy on Rezolute: Clear Drug Activity, High-Need Patient Benefit, and Upcoming FDA Catalysts Support Attractive Risk-Reward
PremiumRatings
Maintaining a Buy on Rezolute: Clear Drug Activity, High-Need Patient Benefit, and Upcoming FDA Catalysts Support Attractive Risk-Reward
3M ago
RZLT
Rezolute (RZLT): Mixed Phase 3 Data, Regulatory Uncertainty in Congenital HI, and Tumor HI Optionality Support Reiterated Hold Rating
PremiumRatings
Rezolute (RZLT): Mixed Phase 3 Data, Regulatory Uncertainty in Congenital HI, and Tumor HI Optionality Support Reiterated Hold Rating
3M ago
RZLT
Rezolute: Favorable Risk-Reward on Ersodetug Despite Mixed sunRIZE Data, Supported by Biomarkers, Breakthrough Designation, and Phase 3 Potential
PremiumRatingsRezolute: Favorable Risk-Reward on Ersodetug Despite Mixed sunRIZE Data, Supported by Biomarkers, Breakthrough Designation, and Phase 3 Potential
3M ago
RZLT
Rezolute shares findings from Expanded Access Program in tumor HI
Premium
The Fly
Rezolute shares findings from Expanded Access Program in tumor HI
3M ago
RZLT
Rezolute shares observations from Phase 3 sunRIZE study in congenital HI
Premium
The Fly
Rezolute shares observations from Phase 3 sunRIZE study in congenital HI
3M ago
RZLT
Rezolute Updates sunRIZE Phase 3 Trial and FDA Plans
PremiumCompany Announcements
Rezolute Updates sunRIZE Phase 3 Trial and FDA Plans
3M ago
8K
RZLT
Rezolute price target lowered to $4 from $20 at Maxim
PremiumThe Fly
Rezolute price target lowered to $4 from $20 at Maxim
4M ago
RZLT
Rezolute price target lowered to $6 from $15 at Guggenheim
PremiumThe Fly
Rezolute price target lowered to $6 from $15 at Guggenheim
4M ago
RZLT
Rezolute price target lowered to $5 from $14 at H.C. Wainwright
PremiumThe Fly
Rezolute price target lowered to $5 from $14 at H.C. Wainwright
4M ago
RZLT
Rezolute downgraded to Hold from Buy at Craig-Hallum
PremiumThe FlyRezolute downgraded to Hold from Buy at Craig-Hallum
4M ago
RZLT
Rezolute price target lowered to $5 from $17 at BTIG
Premium
The Fly
Rezolute price target lowered to $5 from $17 at BTIG
4M ago
RZLT
Rezolute downgraded to Market Perform from Outperform at Citizens
Premium
The Fly
Rezolute downgraded to Market Perform from Outperform at Citizens
4M ago
RZLT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >